Stockscreener 앱 받기
16.43
6.07%
0.94
시장 영업 전:
16.38
-0.05
-0.30%
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
How (KALV) Movements Inform Risk Allocation Models - Stock Traders Daily
KalVista Pharmaceuticals Inc (HAM:4XC1) Stock Earnings Transcripts - GuruFocus
KalVista Pharmaceuticals Inc (HAM:4XC1) Dividend - GuruFocus
KalVista Pharmaceuticals Inc (HAM:4XC1) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Wall Street analysts think KalVista Pharmaceuticals (KALV) could surge 117.1%: Read this before placing a bet - MSN
Breakout Watch: Is KalVista Pharmaceuticals Inc subject to activist investor interestQuarterly Growth Report & Technical Pattern Alert System - baoquankhu1.vn
Kalvista Pharmaceuticals Inc (KALV) announced that it will release its financial results for the first eight months of fiscal year 2025 on March 25, 2026, and will also provide an update on the latest developments in the company's business. - Bitget
Kalvista Pharmaceuticals To Report Eight Months Fiscal Year 2025 Financial Results And Provide Corporate Update On March 25, 2026 - TradingView
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 - The Joplin Globe
Gap Down: Should I hold or sell KalVista Pharmaceuticals Inc now2026 Volume & Fast Entry High Yield Tips - baoquankhu1.vn
KalVista Pharmaceuticals (KALV) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Equities Analysts Issue Forecasts for KALV Q2 Earnings - MarketBeat
Boxer Capital Management LLC Decreases Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Suvretta Capital Management LLC Reduces Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
What is HC Wainwright's Estimate for KALV FY2027 Earnings? - MarketBeat
Hedge Fund Bets: Can KalVista Pharmaceuticals Inc deliver consistent dividendsShort Setup & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
KalVista Pharmaceuticals executive Nicole Sweeny honored as MMM Women of Distinction award recipient - Traders Union
KalVista Pharmaceuticals: Has Potential But With Caveats (NASDAQ:KALV) - Seeking Alpha
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects - MSN
KalVista Pharmaceuticals stock sees RS rating jump to 86 - MSN
KalVista Stock Pre-Market (-0.2%): CEO Stock Sale for Tax Purposes Reported in SEC Filing - Trefis
Jefferies Financial Group Inc. Takes $3.49 Million Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells 6,693 Shares of Stock - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Trading 7.1% HigherHere's Why - MarketBeat
Trading Systems Reacting to (KALV) Volatility - Stock Traders Daily
Blue Owl Capital Holdings LP Invests $1.52 Million in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart - Stocktwits
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2026 - BioSpace
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Crosses Above 50-Day Moving AverageHere's Why - MarketBeat
KalVista presents sebetralstat data showing early treatment impact - Investing.com
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) - BioSpace
KalVista presents sebetralstat data showing early treatment impact By Investing.com - Investing.com India
Market Trends: How does KalVista Pharmaceuticals Inc perform in inflationary periodsWatch List & Low Risk Growth Stock Ideas - baoquankhu1.vn
KalVista Pharmaceuticals, Inc. (KALV): Investor Outlook with a Promising 115% Upside Potential - DirectorsTalk Interviews
Ekterly use urged for kids with HAE 12 and older in new international guideline - Angioedema News
How Kalvista Pharmaceuticals Inc. (KALV) Affects Rotational Strategy Timing - Stock Traders Daily
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - The Joplin Globe
KalVista Pharma chief development officer sells $67,668 in stock - Investing.com UK
KalVista Pharma CCO Sweeny Sold $61,878 in Stock - Investing.com UK
Kalvista Pharma CFO Piekos sells $27,506 in shares By Investing.com - Investing.com Australia
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 5,354 Shares of Stock - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,034 Shares - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $61,890.75 in Stock - MarketBeat
KalVista Pharma CMO Audhya sells $83k in shares - Investing.com South Africa
Kalvista Pharma CEO Palleiko sells $156k in shares to cover tax obligations - Investing.com Australia
KalVista Pharma chief development officer sells $67,668 in stock By Investing.com - Investing.com Canada
Kalvista Pharma CFO Piekos sells $27,506 in shares - Investing.com
KalVista Pharma CMO Audhya sells $83k in shares By Investing.com - Investing.com Canada
[Form 4] KalVista Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
KalVista (NASDAQ: KALV) CFO details RSU vesting and sell-to-cover sale - Stock Titan
1.20%
0.06%
자본화:
|
볼륨(24시간):